Tap, William

Publications

Sort by

Co-Author Network

selected publications

Imaging features and clinical course of undifferentiated round cell sarcomas with CIC-DUX4 and BCOR-CCNB3 translocations. Skeletal radiology. 2020 Academic Article GET IT
Times cited: 17
Mesenchymal chondrosarcoma: imaging features and clinical findings. Skeletal radiology. 2020 Academic Article GET IT
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. The Lancet. Oncology. 2020 Academic Article GET IT
Times cited: 54
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 65
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 91
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA oncology. 2020 Academic Article GET IT
Times cited: 131
Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2019 Academic Article GET IT
Times cited: 96
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet (London, England). 2019 Academic Article GET IT
Times cited: 291
Multidisciplinary care in tenosynovial giant cell tumours. The Lancet. Oncology. 2019 Article GET IT
Times cited: 3
Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. Cancer chemotherapy and pharmacology. 2018 Academic Article GET IT
Times cited: 8
TOMAS: revisiting PARP inhibitor combination therapy. The Lancet. Oncology. 2018 Article GET IT
Times cited: 1
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. The oncologist. 2018 Academic Article GET IT
Times cited: 14
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational new drugs. 2018 Academic Article GET IT
Times cited: 33
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 ^c259T Cells in Synovial Sarcoma. Cancer discovery. 2018 Academic Article GET IT
Times cited: 320
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. The American journal of surgical pathology. 2018 Academic Article GET IT
Times cited: 181
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene. 2018 Academic Article GET IT
Times cited: 33
Locally Aggressive Connective Tissue Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Information Resource GET IT
Times cited: 51
Oncologist use and perception of large panel next-generation tumor sequencing. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 32
ATRX is a regulator of therapy induced senescence in human cells. Nature communications. 2017 Academic Article GET IT
Times cited: 56
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA oncology. 2017 Academic Article GET IT
Times cited: 91
Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases. The American journal of surgical pathology. 2017 Academic Article GET IT
Times cited: 295
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma. Cancer research. 2017 Academic Article GET IT
Times cited: 17
Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. The Journal of thoracic and cardiovascular surgery. 2017 Academic Article GET IT
Times cited: 92
Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation. Cellular signalling. 2017 Academic Article GET IT
Times cited: 15
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 107
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 129
Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy. Oncotarget. 2016 Academic Article GET IT
Times cited: 16
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet (London, England). 2016 Academic Article GET IT
Times cited: 503
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma. Sarcoma. 2016 Academic Article GET IT
Times cited: 10
Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations. The American journal of surgical pathology. 2016 Academic Article GET IT
Times cited: 163
Patient-reported Symptoms of Tenosynovial Giant Cell Tumors. Clinical therapeutics. 2016 Academic Article GET IT
Times cited: 74
Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. The spine journal : official journal of the North American Spine Society. 2016 Academic Article GET IT
Times cited: 31
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. The oncologist. 2015 Academic Article GET IT
Times cited: 23
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas. PloS one. 2015 Academic Article GET IT
Times cited: 31
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. European journal of cancer. 2015 Academic Article GET IT
Times cited: 80
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 244
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology. 2015 Academic Article GET IT
Times cited: 44
Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas. British journal of cancer. 2015 Academic Article GET IT
Times cited: 23
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015 Academic Article GET IT
Times cited: 50
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget. 2015 Academic Article GET IT
Times cited: 104
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma. Cancer chemotherapy and pharmacology. 2015 Academic Article GET IT
Times cited: 24
Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome. Neoplasia (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 36
Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer discovery. 2015 Academic Article GET IT
Times cited: 113
Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature. International journal of radiation oncology, biology, physics. 2014 Academic Article GET IT
Times cited: 9
MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 92
Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes, chromosomes & cancer. 2014 Academic Article GET IT
Times cited: 30
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human pathology. 2014 Academic Article GET IT
Times cited: 241
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature genetics. 2014 Academic Article GET IT
Times cited: 451
Phosphoproteomic profiling reveals IL6-mediated paracrine signaling within the Ewing sarcoma family of tumors. Molecular cancer research : MCR. 2014 Academic Article GET IT
Times cited: 14
Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 89
Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine. International journal of radiation oncology, biology, physics. 2014 Academic Article GET IT
Times cited: 83
Sarcoma immunotherapy: past approaches and future directions. Sarcoma. 2014 Information Resource GET IT
Times cited: 44
High-risk features in radiation-associated breast angiosarcomas. British journal of cancer. 2013 Academic Article GET IT
Times cited: 58
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 360
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 176
Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition. The American journal of pathology. 2013 Academic Article GET IT
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 32
Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment. Cancer discovery. 2012 Academic Article GET IT
Times cited: 31
Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor. Annals of surgical oncology. 2012 Academic Article GET IT
Times cited: 71
Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas. Expert review of anticancer therapy. 2012 Information Resource GET IT
Times cited: 11
Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatric research. 2012 Information Resource GET IT
Times cited: 39
Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. American journal of hypertension. 2012 Academic Article GET IT
Times cited: 43
Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012 Academic Article GET IT
Times cited: 78
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 210
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 148
18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 79
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer. 2011 Academic Article GET IT
Times cited: 38
Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes, chromosomes & cancer. 2011 Academic Article GET IT
Times cited: 62
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010 Academic Article GET IT
Times cited: 19
Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram. Cancer. 2010 Academic Article GET IT
Times cited: 40
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (New York, N.Y.). 2010 Academic Article GET IT
Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010 Academic Article GET IT
Times cited: 59
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. Sarcoma. 2010 Academic Article GET IT
Times cited: 31
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010 Academic Article GET IT
Times cited: 160
Utilization of positron emission tomography in the management of patients with sarcoma. Current opinion in oncology. 2009 Information Resource GET IT
Times cited: 72
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 160
The multidisciplinary management of osteosarcoma. Current treatment options in oncology. 2009 Information Resource GET IT
Times cited: 100
Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 146
Targeted therapies for soft-tissue sarcomas. Expert review of anticancer therapy. 2007 Information Resource GET IT
Times cited: 5
Advances in chemotherapy for patients with extremity soft tissue sarcoma. The Orthopedic clinics of North America. 2006 Information Resource GET IT
Times cited: 15
Quasi-native chaperonin-bound intermediates in facilitated protein folding. The Journal of biological chemistry. 1995 Academic Article GET IT
Times cited: 59

more ...

less ...

Background

education and training

B.S., Bucknell University 91
M.D., Jefferson Medical College, Thomas Jefferson University 2000

Contact

full name

William Tap

VIVO Weill Cornell Medical College

William Tap Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name